Slide 1: FY 2025 Report: Strong Execution, Sustained Company Growth
FY 2025 Report Strong Execution, Sustained Company Growth Capital Market Earnings Call 26 February 2026
Slide 2: Disclaimer & Safe Harbor
Disclaimer & Safe Harbor This document contains forward-looking statements, including, without limitation, statements containing the words “potential”, “believes”, “anticipates”, “expects”, “intends”, “plans”, “seeks”, “estimates”, “may”, “will”, “continue” and similar expressions. These forward-loo
Slide 3: Agenda
Agenda 1 2 3 4 5 Proprietary and Confidential Property of UCB Delivering with Innovating with Executing with Growing with Advancing from a Confidence Purpose Impact Discipline Position of Strength Jean-Christophe Emmanuel Fiona Sandrine Jean-Christophe Tellier Caeymaex du Monceau Dufour Tellier Chie
Slide 4: Delivering with Confidence
Proprietary and Confidential Property of UCB Delivering with Confidence Jean-Christophe Tellier Chief Executive Officer UCB – FY results 2025, February 2026 4
Slide 5: 2025: A year of strong delivery & execution
2025: A year of strong delivery & execution Strong 2025 Performance Significant investment in mammalian antibody campus in the U.S. COMBINED NET SALES $ 5bn 2 EXECUTION 3.3bn (>2x) Proprietary and Confidential Property of UCB REVENUE: EXCELLENCE € 7.7 bn 5 growth drivers U.S. CMO NETWORK EXPANSION +
Slide 6: Promising future built on a distinct position of strength
Promising future built on a distinct position of strength Patent Protection* 2033 2035 2037 DIFFERENTIATED FIRST AGENT FIRST AND ONLY Proprietary and Confidential Property of UCB SOLUTIONS FOUNDATIONAL therapy in DS for anti-AChR+ & anti-MuSK+ gMG IL-17A & IL-17F inhibitor RECOGNIZED option in LGS O
Slide 7: Innovating with Purpose
Proprietary and Confidential Property of UCB Innovating with Purpose Emmanuel Caeymaex Head of Patient Evidence UCB – FY results 2025, February 2026 7
Slide 8: Rich pipeline to deliver innovation into the future
Rich pipeline to deliver innovation into the future Phase 1 Phase 2 Phase 3 Phase 4 Indication & status/next milestone bimekizumab (IL-17 A/F) — BE BOLD Post-approval head-to-head study versus risankizumab in PsA - NEW H1 2026 bimekizumab (IL-17 A/F) NEW Palmoplantar pustulosis (PPP) 2028 Proprietar
Slide 9: Galvokimig: High potential in Atopic Dermatitis and expanding beyond
Galvokimig: High potential in Atopic Dermatitis and expanding beyond Mechanism of AtD pathogenesis1,# Proprietary and Confidential Property of UCB Atopic Dermatitis CODP & NCFB Two new respiratory indications involving both type 2 and 3 Addressing disease heterogeneity beyond Th2 biology inflammatio
Slide 10: FINTEPLA: Growing across Developmental and Epileptic Encephalopathies & beyond
FINTEPLA: Growing across Developmental and Epileptic Encephalopathies & beyond Transformative therapy for multiple DEEs & evolving to neurodevelopmental disorders RETT Syndrome Proprietary and Confidential Property of UCB CDKL5 Deficiency Disorder RETT Syndrome, a new potential indication ~19k Lenno
Slide 11: KYGEVVI: Changing the course of TK2d with proven survival impact
KYGEVVI: Changing the course of TK2d with proven survival impact first and only approved treatment for adult and pediatric patients First and only approved treatment for adult and Thymidine Kinase 2 deficiency* pediatric TK2d patients Proprietary and Confidential Property of UCB Approved in the U.S.
Slide 12: Executing with Impact
Proprietary and Confidential Property of UCB Executing with Impact Fiona du Monceau Chief Commercial Officer UCB – FY results 2025, February 2026 12
Slide 13: Reaching more patients, delivering greater impact with BIMZELX
Reaching more patients, delivering greater impact with BIMZELX® BIMZELX® GLOBAL BIMZELX® U.S. UPTAKE KEY HIGHLIGHTS TOTAL BIMZELX PATIENTS (R3M) All indications combined >50 >116k >€2.2bn Patient adoption outpacing analogues countries patients net sales Proprietary and Confidential Property of UCB a
Slide 14: Strengthening BIMZELX leadership in hidradenitis suppurativa care
Strengthening BIMZELX® leadership in hidradenitis suppurativa care BIMZELX® UPTAKE IN HS GLOBAL HS MARKET PERFORMANCE & OUTLOOK DYNAMIC PATIENT SHARE >32% IN 10 MONTHS1 TOTAL PATIENTS ON BIOLOGICS3 24% ~68k YoY HS Proprietary and Confidential Property of UCB commercial launch ~55k HS approval 32% Ot
Slide 15: Advancing targeted therapies in high-need rare indications
Advancing targeted therapies in high-need rare indications First & only company offering a unique dual-therapy portfolio Proprietary and Confidential Property of UCB 30+ ~3,700 >€500M countries approved patients treated combined net sales 20 LGS 9 % of patients % of patients1 DS 1 Foundational thera
Slide 16: Growing with Discipline
Proprietary and Confidential Property of UCB Growing with Discipline Sandrine Dufour Chief Financial Officer UCB – FY results 2025, February 2026 16
Slide 17: Strong launch execution & disciplined value creation
Strong launch execution & disciplined value creation 2025 Product Net Sales % Growth vs. FY24 >200% € 2 227M 2227 +26% 5 GROWTH € 427M 427 DRIVERS Proprietary and Confidential Property of UCB +65% COMBINED € 332M 332 NET SALES >2x 3x €217 217M +33% € 137M 137 Advancing on our sustainability journey
Slide 18: 2025: building momentum for long-term growth
2025: building momentum for long-term growth FY 2025* Actual CER Revenue Net Sales € 7 388M (+32%; +35% CER) – Strong growth from the continued launches of the five growth drivers and with BIMZELX® exceeding expectations through strong demand and favorable U.S. payer mix, in particular in HS. 7 741
Slide 19: 2026 guidance: built on delivered milestones, committed to continued growth
2026 guidance: built on delivered milestones, committed to continued growth Based on current rules and regulations Revenues High single-digit % to low expected to grow • Strong performance of 5 growth drivers (at CER) double-digit • BIMZELX® access expansion & net pricing dynamics • BRIVIACT® LOE Pr
Slide 20: Advancing From a Position of Strength
Proprietary and Confidential Property of UCB Advancing From a Position of Strength Jean-Christophe Tellier Chief Executive Officer UCB – FY results 2025, February 2026 20
Slide 21: A position of strength
A position of strength . . . driving growth for a decade+ Proprietary and Confidential Property of UCB Differentiated innovation Executing with agility and Purpose-led performance, translating science into new resilience to deliver creating long-term value and targeted therapies future solutions for
Slide 22: Thank you.
Thank you. Proprietary and Confidential Property of UCB